00:00:15
High-risk regulatory claim
reports Alabama’s notice barring clinicians from research-grade peptide use.
Review topic: state regulation.
Checked against: Official notice concerning prescribing non-FDA-approved research-grade peptides
Video claim watch
Doctor Breaks Down Peptide Safety
A concise national-news segment shows which peptide safety questions are reaching a general audience.
CBS News channel3:06 runtime3.4K views when checked
Transcript review
6 material claims logged
Published with source gaps audit stateauto-captioned transcript0 operational-guidance flags4 source gaps
Reviewed Jul 12, 2026. Next review Aug 12, 2026.
timely regulatory summary; some counts and adverse-event claims need primary documentation.
auto-caption available; no chapters.
Claim-by-claim audit
What the video says, and what needs checking
00:00:43
High-risk regulatory claim
distinguishes naturally occurring/approved peptide drugs from untested research-only peptides.
Review topic: category.
Checked against: FDA BPC-157 compounding safety risk: immunogenicity
approved labels.
00:01:07
High-risk commercial claimHigh-risk regulatory claim
says unapproved products are sold for weight loss, muscle gain, and anti-aging.
Review topic: claims landscape.
Checked against: Primary-source record still needed
FDA warning letters.
00:01:43
High-risk commercial claim
reports more than 400 promotional videos and 14 million views, with affiliate compensation.
Review topic: media/influencer market.
Checked against: Primary-source record still needed
preserve search methodology and disclosure screenshots.
00:02:25
High-risk regulatory claim
discusses federal-state tension and a July FDA panel.
Review topic: policy.
Checked against: Primary-source record still needed
FDA advisory calendar; do not imply the meeting’s outcome before it happens.
00:02:45
High-risk safety claimHigh-risk quality claim
reports two women ventilated after injections and claims testing found contaminants/wrong drugs.
Review topic: adverse events/product identity.
Checked against: Primary-source record still needed
FDA/clinical/lab records required before repeating specifics.
Source check
Records used in this claim audit
Official notice concerning prescribing non-FDA-approved research-grade peptides
State medical-board notice addressing prescribing of non-FDA-approved research-grade peptides.
1 linked pageOpen original ·
alabama-board-research-peptides-noticeCertain bulk drug substances for use in compounding may present significant safety risks
FDA risk page lists BPC-157: compounded BPC-157 may pose immunogenicity risk and peptide-related impurity concerns for certain routes of administration.
41 linked pagesOpen original ·
fda-bulk-risk-list